CD22 CAR T-cell therapy

CD22-targeted chimeric antigen receptor (CAR) T-cell therapy is an adoptive cellular immunotherapy designed to treat B-cell malignancies, most notably relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The therapy involves genetically engineering a patient's T cells to express a CAR that specifically recognizes and binds to CD22, a surface antigen widely expressed on mature B cells and most B-cell lineage leukemias. It has demonstrated significant clinical activity, particularly as a salvage treatment for patients who have failed CD19-targeted CAR T-cell therapies. Research into resistance mechanisms has identified that while antigen loss can occur, resistance can also be driven by antigen-independent pathways. Specifically, deficiency in the Golgi-resident protease SPPL3 leads to dysregulated glycosylation (mediated by glycosyltransferases like B3GNT2), which impairs the sensitivity of leukemic cells to CAR T-cell-mediated cytotoxicity and blunts immune sensing without reducing CD22 surface expression.

Other names

CD22-directed CAR T-cell therapyCD-22-directed CAR T-cell therapyCD 22-directed CAR T-cell therapyanti-CD22 CAR-Tanti-CD-22 CAR-Tanti-CD 22 CAR-TCD22 CAR-TCD-22 CAR-TCD 22 CAR-T